Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$12.49
+2.4%
$7.22
$3.72
$12.95
$1.42B1.881.63 million shs3.68 million shs
CureVac N.V. stock logo
CVAC
CureVac
$5.39
-0.2%
$4.85
$2.37
$5.72
$1.21B2.53778,986 shs1.01 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$29.41
-1.1%
$25.77
$16.16
$31.80
$1.19B0.75224,944 shs353,025 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$2.21
-7.1%
$0.82
$0.13
$3.29
$276.16M2.044.95 million shs7.12 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
+2.38%+13.75%+72.51%+185.81%+39.09%
CureVac N.V. stock logo
CVAC
CureVac
-0.19%-1.28%-1.82%+72.76%+47.67%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-1.08%-4.51%+22.75%+70.10%+54.63%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-7.14%-11.60%+932.71%+240.00%+121.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
3.5402 of 5 stars
4.43.00.00.02.81.70.6
CureVac N.V. stock logo
CVAC
CureVac
4.0737 of 5 stars
4.15.00.04.90.00.01.3
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
4.0506 of 5 stars
0.94.02.51.13.33.32.5
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
3.839 of 5 stars
4.35.00.00.02.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
2.82
Moderate Buy$18.7049.72% Upside
CureVac N.V. stock logo
CVAC
CureVac
2.20
Hold$6.8326.78% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.83
Reduce$24.40-17.04% Downside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.60
Moderate Buy$5.63154.69% Upside

Current Analyst Ratings Breakdown

Latest VOR, PAHC, COGT, and CVAC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/18/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $22.00
7/10/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$25.00 ➝ $29.00
7/8/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $22.00
7/8/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00
7/8/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$7.00 ➝ $9.00
7/7/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$23.00 ➝ $28.00
7/7/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$16.00 ➝ $18.00
7/7/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$25.00 ➝ $35.00
6/30/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$10.00
6/30/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$3.00
6/26/2025
CureVac N.V. stock logo
CVAC
CureVac
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Neutral$12.00 ➝ $5.50
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/A$1.32 per shareN/A
CureVac N.V. stock logo
CVAC
CureVac
$579.18M2.09$0.87 per share6.17$3.36 per share1.60
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.02B1.17$2.11 per share13.91$6.34 per share4.64
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$255.86M-$1.840.00N/AN/AN/A-149.79%-75.61%8/5/2025 (Estimated)
CureVac N.V. stock logo
CVAC
CureVac
$175.50M$0.925.86N/AN/A35.44%30.89%25.54%8/13/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$2.42M$0.7815.2414.000.492.68%30.51%6.89%8/27/2025 (Estimated)
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/A-$1.51N/AN/AN/AN/AN/AN/AN/A

Latest VOR, PAHC, COGT, and CVAC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
CureVac N.V. stock logo
CVAC
CureVac
-$0.15N/AN/AN/A$4.27 millionN/A
8/5/2025Q2 2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$0.54N/AN/AN/AN/AN/A
5/22/2025Q1 2025
CureVac N.V. stock logo
CVAC
CureVac
-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million
5/7/2025Q3 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
5/6/2025Q1 2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$0.56-$0.52+$0.04-$0.52N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/AN/A
CureVac N.V. stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.63%N/A61.54%N/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A

Latest VOR, PAHC, COGT, and CVAC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
5.13
5.13
CureVac N.V. stock logo
CVAC
CureVac
0.05
7.65
7.64
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.67
2.91
1.23
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
CureVac N.V. stock logo
CVAC
CureVac
17.26%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
7.29%
CureVac N.V. stock logo
CVAC
CureVac
2.15%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.07%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
80113.86 million105.56 millionOptionable
CureVac N.V. stock logo
CVAC
CureVac
880224.34 million219.52 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1,94040.53 million20.24 millionOptionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
140124.96 million65.45 millionNot Optionable

Recent News About These Companies

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
Vor Biopharma Sees Unusually Large Options Volume (NYSE:VOR)
Vor Biopharma (NYSE:VOR) Upgraded at HC Wainwright
Vor Biopharma (NYSE:VOR) Gains Momentum S&P 500
Vor Biopharma Inc. Stock Grades - Barron's

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:COGT

$12.49 +0.29 (+2.38%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$12.48 -0.01 (-0.08%)
As of 07/18/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

CureVac stock logo

CureVac NASDAQ:CVAC

$5.39 -0.01 (-0.19%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$5.48 +0.10 (+1.76%)
As of 07/18/2025 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$29.41 -0.32 (-1.08%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$29.44 +0.03 (+0.10%)
As of 07/18/2025 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Vor Biopharma stock logo

Vor Biopharma NYSE:VOR

$2.21 -0.17 (-7.14%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.24 +0.04 (+1.58%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.